Tag Archives: announcement

Thoughts on Astellas’s Strategic Investment in Poseida; Astellas Gains Rights over P-MUC1C-ALLO1 Program; First Patient in P-CD19CD20-ALLO1 Trial to Be Dosed in Early 2024; Gracell Announces Private Investment

On Monday, August 7, Poseida and Astellas announced (press release) a strategic investment to support the advancement of Poseida’s cell therapy assets in solid tumors with Astellas receiving the right of exclusive negotiation and first refusal to license P-MUC1C-ALLO1 (allogeneic MUC1C CAR-T). Additionally, Poseida provided (press release) a business update on its allogeneic CAR-T programs and Gracell reported (press release) up to $150M in private placement financing by a syndicate of premier healthcare investors. Below, Celltelligence provides insights on Astellas’s interest in allogeneic cell therapies, while discussing how Poseida and Gracell could benefit from these investments.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision Receives Feedback from the FDA on Azer-cel’s Registrational Pathway

On Thursday, July 27, Precision Biosciences announced (press release) the receipt of final Type B meeting minutes from the FDA providing clarity on the potential registrational pathway of its lead asset azer-cel (PBCAR0191; allogeneic CD19 CAR-T). Moreover, the company disclosed discussions with multiple potential strategic partners for the development of its cell therapy assets. Below, Celltelligence provides insights on azer-cel’s potential in LBCL, while comparing the asset with its main allogeneic competitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.